{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:09:27Z","timestamp":1769087367020,"version":"3.49.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.cyto.2025.157044","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T01:27:46Z","timestamp":1759541266000},"page":"157044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The significance of serum IL-18 levels in Hodgkin lymphoma patients"],"prefix":"10.1016","volume":"196","author":[{"given":"G\u00fclden","family":"Sincan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suat","family":"Sincan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c7a\u011fr\u0131","family":"K\u0131z\u0131ltun\u00e7","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esra","family":"E\u011filmez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2025.157044_bb0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.biopha.2014.12.040","article-title":"Clinical significance of serum interleukin-18 (IL-18) levels in patients with gastric cancer","volume":"70","author":"Tas","year":"2015","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.cyto.2025.157044_bb0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S1359-6101(98)00004-5","article-title":"Interleukin-18: perspectives on the newest interleukin","volume":"9","author":"Gillespie","year":"1998","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.cyto.2025.157044_bb0015","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.4049\/jimmunol.156.11.4274","article-title":"Cloning of the cDNA for human IFN-gamma-inducing factor, expression in Escherichia coli, and studies on the biologic activities of the protein","volume":"156","author":"Ushio","year":"1996","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2025.157044_bb0020","first-page":"329","article-title":"The dual effects of interleukin-18 in tumor progression","volume":"4","author":"Park","year":"2007","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.cyto.2025.157044_bb0025","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.bbrc.2015.02.108","article-title":"Interleukin-18 enhances breast cancer cell migration via down-regulation of claudin-12 and induction of the p38 MAPK pathway","volume":"459","author":"Yang","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"12","key":"10.1016\/j.cyto.2025.157044_bb0030","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/carcin\/bgp158","article-title":"Interleukin-18 increases metastasis and immune escape of stomach cancer via the downregulation of CD70 and maintenance of CD44","volume":"30","author":"Kang","year":"2009","journal-title":"Carcinogenesis"},{"issue":"11","key":"10.1016\/j.cyto.2025.157044_bb0035","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1515\/hsz-2016-0215","article-title":"IL-1 family cytokines in cancer immunity - a matter of life and death","volume":"397","author":"Mora","year":"2016","journal-title":"Biol. Chem."},{"issue":"2","key":"10.1016\/j.cyto.2025.157044_bb0040","doi-asserted-by":"crossref","DOI":"10.1177\/1559325820931360","article-title":"Prognostic role of IL-18 in various human cancers and radiation injuries: a meta-analysis","volume":"18","author":"Yao","year":"2020","journal-title":"Dose-Response"},{"issue":"1","key":"10.1016\/j.cyto.2025.157044_bb0045","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.gene.2015.03.010","article-title":"Interleukin 18 augments growth ability via NF-\u03baB and p38\/ATF2 pathways by targeting cyclin B1, cyclin B2, cyclin A2, and Bcl-2 in BRL-3A rat liver cells","volume":"563","author":"Zhang","year":"2015","journal-title":"Gene"},{"issue":"9","key":"10.1016\/j.cyto.2025.157044_bb0050","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1084\/jem.20171810","article-title":"BCAP links IL-1R to the PI3K-mTOR pathway and regulates pathogenic Th17 cell differentiation","volume":"215","author":"Deason","year":"2018","journal-title":"J. Exp. Med."},{"issue":"16","key":"10.1016\/j.cyto.2025.157044_bb0055","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"IL-18 induces PD-1\u2013dependent immunosuppression in Cancer","volume":"71","author":"Terme","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2025.157044_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmic.2020.100023","article-title":"Analysis of the intestinal microbiota in COVID-19 patients and its correlation with the inflammatory factor IL-18","volume":"5","author":"Tao","year":"2020","journal-title":"Med. Microecol."},{"issue":"8","key":"10.1016\/j.cyto.2025.157044_bb0065","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.3390\/cancers15082284","article-title":"Intestinal microbes and hematological malignancies","volume":"15","author":"Zhu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.cyto.2025.157044_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.919973","article-title":"Interleukin-18 cytokine in immunity, inflammation, and autoimmunity: biological role in induction, regulation, and treatment","volume":"13","author":"Ihim","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2025.157044_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-1759(97)00094-X","article-title":"Characterization of anti-human interleukin-18 (IL-18)\/ interferon-gamma-inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA","volume":"206","author":"Taniguchi","year":"1997","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cyto.2025.157044_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1163\/15685590051129850","article-title":"Serum IL-18 levels in patients with various hematological disorders","volume":"30","author":"Takubo","year":"2000","journal-title":"Haematologia (Budap)"},{"key":"10.1016\/j.cyto.2025.157044_bb0085","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1046\/j.1365-2133.2001.04420.x","article-title":"Serum levels of interleukin-18 are increased in patients with cutaneous T-cell lymphoma and cutaneous natural killer-cell lymphoma","volume":"145","author":"Amo","year":"2001","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.cyto.2025.157044_bb0090","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1182\/blood.V104.11.4543.4543","article-title":"Serum Interleukin-18 levels are associated with response to treatment and survival in patients with aggressive non-Hodgkin\u2019s lymphoma","volume":"104","author":"Goto","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.cyto.2025.157044_bb0095","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000046520","article-title":"Comparative study on complete remission rate and overall survival in three groups classified based on the serum interleukin-18 level in non-Hodgkin\u2019 s lymphoma patients","volume":"104","author":"Takubo","year":"2000","journal-title":"Acta Haematol."},{"issue":"10","key":"10.1016\/j.cyto.2025.157044_bb0100","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/cancers12102789","article-title":"Interleukin-18 and hematopoietic recovery after allogeneic stem cell","volume":"12","author":"Radujkovic","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.cyto.2025.157044_bb0105","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1182\/blood.V98.7.2101","article-title":"Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice","volume":"98","author":"Ogura","year":"2001","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.cyto.2025.157044_bb0110","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.21873\/anticanres.13691","article-title":"High serum levels of Interleukin-18 are associated with worse outcomes in patients with breast Cancer","volume":"39","author":"Inoue","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.cyto.2025.157044_bb0115","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.4049\/jimmunol.1002046","article-title":"IL-18 production downstream of the Nlrp3 inflammasome confers protection against colorectal tumor formation","volume":"185","author":"Zaki","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.cyto.2025.157044_bb0120","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1600-0609.2011.01649.x","article-title":"Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens","volume":"87","author":"Goto","year":"2011","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.cyto.2025.157044_bb0125","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/0008-5472.CAN-15-1548","article-title":"Inflammation-dependent IL18 signaling restricts hepatocellular carcinoma growth by enhancing the accumulation and activity of tumor-infiltrating lymphocytes","volume":"76","author":"Markowitz","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.cyto.2025.157044_bb0130","first-page":"51","article-title":"Importance of serum IL-18 and RANTES as markers for breast carcinoma progression","volume":"17","author":"Eissa","year":"2005","journal-title":"J. Egypt. Natl. Canc. Inst."},{"key":"10.1016\/j.cyto.2025.157044_bb0135","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1172\/JCI1379","article-title":"Interleukin18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells","volume":"101","author":"Puren","year":"1998","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cyto.2025.157044_bb0140","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.4049\/jimmunol.162.2.1096","article-title":"IL-18 is produced by articular chondrocytes and induces proinflammatory and catabolic responses","volume":"162","author":"Olee","year":"1999","journal-title":"J. Immunol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466625001917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:16:50Z","timestamp":1762593410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466625001917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":28,"alternative-id":["S1043466625001917"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157044","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The significance of serum IL-18 levels in Hodgkin lymphoma patients","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2025.157044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"157044"}}